2,2-diethoxy-N-[[4-(trifluoromethyl)phenyl]methyl]ethanamine | 1421492-80-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,2-diethoxy-N-[[4-(trifluoromethyl)phenyl]methyl]ethanamine
• CAS: 1421492-80-9
• 化学式: C₁₄H₂₀F₃NO₂
• 分子量: 291.314
• InChiKey: YUHJRKFAHQXVTO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  20
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  30.5
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  氨基乙醛缩二乙醇 在 氢溴酸 、 sodium hydride 、 溶剂黄146 、 sodium hydroxide 、 苯酚 作用下， 以 二氯甲烷 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 反应 48.0h， 生成 2,2-diethoxy-N-[[4-(trifluoromethyl)phenyl]methyl]ethanamine
  参考文献：
  名称：

  Design, development and evaluation of novel dual PPARδ/PPARγ agonists

  摘要：

  Type 2 diabetes is at epidemic proportions and thus development of novel pharmaceutical therapies for improving insulin sensitivity has become of paramount importance. The objectives of the current study were to develop novel dual PPAR gamma/delta agonists without the deleterious side effects associated with full PPAR gamma agonists. Docking simulations of 23 novel compounds within the ligand binding domain of PPAR gamma/delta were performed using AutoDock Vina which consistently reproduced experimental binding poses from known PPAR agonists. Comparisons were made and described with other docking programs AutoDock and Surflex-Dock (from SYBYL-X). Biological evaluation of compounds was accomplished by transcriptional promoter activity assays, quantitative PCR gene analysis for known PPAR gamma/delta targets as well as in vitro assays for lipid accumulation and mitochondrial biogenesis verses known PPAR agonists. We found one (compound 9) out of the 23 compounds evaluated, to be the most potent and selective dual PPAR gamma/delta agonist which did not display the deleterious side effects associated with full PPAR gamma agonists. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.11.060

文献信息

• Dual PPAR-δ PPAR-γ agonists
  申请人：Amin Rajesh

  公开号：US09422239B1

  公开（公告）日：2016-08-23

  The present disclosure provides novel compounds with activity as PPARβ/δ and PPARγ dual agonists. The disclosure also provides methods of treating diabetes mellitus and methods of treating Alzheimer's disease utilizing the novel compounds, as well as pharmaceutical formulations comprising the novel compounds.

  本公开提供了具有PPARβ/δ和PPARγ双激动剂活性的新化合物。本公开还提供了利用这些新化合物治疗糖尿病和治疗阿尔茨海默病的方法，以及包含这些新化合物的药物配方。
• US9422239B1
  申请人：——

  公开号：US9422239B1

  公开（公告）日：2016-08-23
• Design, development and evaluation of novel dual PPARδ/PPARγ agonists
  作者：Symon Gathiaka、Gayani Nanayakkara、Tracey Boncher、Orlando Acevedo、Johnathon Wyble、Sagar Patel、Akash Patel、Mary Elizabeth Shane、Blake Bonkowski、Jason Wieczorek、Yinghui Rong、Kevin Huggins、Forest Smith、Rajesh H. Amin

  DOI：10.1016/j.bmcl.2012.11.060

  日期：2013.2

  Type 2 diabetes is at epidemic proportions and thus development of novel pharmaceutical therapies for improving insulin sensitivity has become of paramount importance. The objectives of the current study were to develop novel dual PPAR gamma/delta agonists without the deleterious side effects associated with full PPAR gamma agonists. Docking simulations of 23 novel compounds within the ligand binding domain of PPAR gamma/delta were performed using AutoDock Vina which consistently reproduced experimental binding poses from known PPAR agonists. Comparisons were made and described with other docking programs AutoDock and Surflex-Dock (from SYBYL-X). Biological evaluation of compounds was accomplished by transcriptional promoter activity assays, quantitative PCR gene analysis for known PPAR gamma/delta targets as well as in vitro assays for lipid accumulation and mitochondrial biogenesis verses known PPAR agonists. We found one (compound 9) out of the 23 compounds evaluated, to be the most potent and selective dual PPAR gamma/delta agonist which did not display the deleterious side effects associated with full PPAR gamma agonists. (c) 2012 Elsevier Ltd. All rights reserved.